United States - English - NLM (National Library of Medicine)

quality care products llc - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to: s. aureus and s. pyogenes . this drug is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

United States - English - NLM (National Library of Medicine)

h.j. harkins company, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to: s. aureus and s. pyogenes . this drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment, 2% is indicated for the topical treatment of impetigo due to: staphylococcus aureus and streptococcus pyogenes . this drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes). mupirocin ointment is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin ointment. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin ointment in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin ointment [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects and miscarriages for the indicated population is unknown. the esti

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - mupirocin (unii: d0gx863oa5) (mupirocin - unii:d0gx863oa5) - mupirocin 20 mg in 1 g - mupirocin ointment usp, 2% is indicated for the topical treatment of impetigo due to: and . s. aureus s. pyogenes this drug is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - mupirocin, quantity: 20 mg/g - ointment - excipient ingredients: macrogol 400; macrogol 3350 - medicianz mupirocin ointment is indicated for the topical treatment of mild impetigo.

Australia - English - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - mupirocin calcium, quantity: 21.5 mg/g (equivalent: mupirocin, qty 20 mg/g) - ointment - excipient ingredients: white soft paraffin; bis-diglyceryl polyacyladipate-2 - medsurge mupirocin nasal ointment is indicated for the elimination of nasal carriage of staphylococci, including methicillin resistant staphylococcus aureus (mrsa).

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - mupirocin calcium (unii: rg38i2p540) (mupirocin - unii:d0gx863oa5) - mupirocin cream usp, 2% is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin cream is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin cream in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin cream [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects a

United States - English - NLM (National Library of Medicine)

northstar rx llc - mupirocin calcium (unii: rg38i2p540) (mupirocin - unii:d0gx863oa5) - mupirocin cream usp, 2% is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin cream is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin cream in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin cream [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background risk of major birth defects a

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - mupirocin calcium (unii: rg38i2p540) (mupirocin - unii:d0gx863oa5) - mupirocin cream usp, 2% is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm 2 in area) due to susceptible isolates of staphylococcus aureus (s. aureus) and streptococcus pyogenes (s. pyogenes) . mupirocin cream is contraindicated in patients with known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. risk summary there are insufficient human data to establish whether there is a drug-associated risk with mupirocin cream in pregnant women. systemic absorption of mupirocin through intact human skin is minimal following topical administration of mupirocin cream [see clinical pharmacology (12.3)] . no developmental toxicity was observed in rats or rabbits treated with mupirocin subcutaneously during organogenesis at doses of 160 or 40 mg per kg per day, respectively (22 and 11 times the human topical dose based on calculations of dose divided by the entire body surface area). the estimated background ris